ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1574

Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography

Rachael Flood1, Aamir Saeed2, Kate Harrington1, Conor Shortt1, Ronan Mullan1 and David Kane1, 1Tallaght University Hospital, Dublin, Ireland, 2Worcestershire Acute Hospitals NHS Trust., Worcester, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Crystal-induced arthritis, gout, hyperuricemia, Imaging, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The diagnostic gold standard for gout remains aspiration and identification of monosodium urate (MSU) crystals under polarised light microscopy. Joint aspiration is invasive and in certain patients may not be possible. The 2015 gout classification criteria include imaging evidence of urate deposition in the diagnostic criteria. The imaging modalities with sufficient published data and investigator experience to support their utility in identifying urate deposition accurately were ultrasound (US) and dual energy computed tomography (DECT). Despite the fact that US and DECT are both candidates to quantify urate deposition and monitor urate depletion, it is still unknown whether these techniques provide similar quantification of the extent of urate deposition in a given patient.

The aim of the study was to compare the quantification of urate deposition by US and DECT in a group of patients with gout and asymptomatic hyperuricaemia (AH).

Methods: Patients with either AH or gout according to 2015 diagnostic criteria were prospectively recruited to undergo quantification of MSU deposition in the knees and feet using US and DECT. A urate quantification score for each imaging modality was calculated, for US images a semiquantitative composite scoring system ( 1= present, 0 = absent) was used to obtain a sum score for total elementary lesions of urate deposition (double contour, tophi, aggregate or erosion) across all four joints. Exact quantification of urate deposition was calculated using specific quantification software and recorded as a deposition urate score during DECT. Gout patients underwent 6 months of treatment with urate lowering therapy (ULT) in a treat to target approach and follow up US and DECT after six months of treatment.

Results: A total of 62 patients (gout=25, AH=21, Control=16) were recruited. Mean (SD) age was 60 (13.11) years in gout, 58 (12.64) years in AH and 36 (8.9) years in control groups. Mean sUA umol/L levels at baseline in gout, AH and control were (398, 472 and 265) respectively.

For the gout cohort the mean (SD) US score at baseline was 3.64 (2.52) and on repeat US following 6 months of ULT this reduced to 2.68 (2.01). In the AH group the mean (SD) US score at baseline was 0.81 (0.98). There is a significant difference (P< 0.01) between the mean baseline US score in Gout and AH patients.

22 and 18 patients underwent baseline DECT imaging of the feet from the Gout and AH groups respectively. The Mean (SD) deposition urate score in the gout cohort at baseline was 0.104 (0.306.) Following 6 months of ULT the mean (SD) urate deposition score was 0.069 (0.246). The mean (SD) deposition urate score in the AH group was 0.782 (0.155).

In the gout cohort of patients there is a significant correlation between the sum US Score and the DECT deposition urate score ( Spearman correlation coefficient .544).

Conclusion: US and DECT imaging modalities demonstrate correlation in urate quantification in patients with gout.


Disclosures: R. Flood, None; A. Saeed, None; K. Harrington, None; C. Shortt, None; R. Mullan, None; D. Kane, None.

To cite this abstract in AMA style:

Flood R, Saeed A, Harrington K, Shortt C, Mullan R, Kane D. Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/comparison-of-urate-quantification-in-gout-and-asymptomatic-hyperuricemia-by-ultrasound-and-dual-energy-computed-tomography/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-urate-quantification-in-gout-and-asymptomatic-hyperuricemia-by-ultrasound-and-dual-energy-computed-tomography/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology